XTL Biopharmaceuticals to acquire Psyga Bio in all-share deal, issuing ADSs equal to 40% of post-deal equity
- XTL will issue additional milestone-based consideration to Psyga Bio stakeholders, subject to the acquired business achieving specified milestones.
- $1.5 million private placement commitment arranged to provide funding support for the Psyga Bio acquisition transaction.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.